• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清浓度可预测危重症患者中替加环素引起的低纤维蛋白原血症:一项回顾性队列研究。

Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: A retrospective cohort study.

机构信息

China Pharmaceutical University, Nanjing Drum Tower Hospital, Nanjing, China.

Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China; Nanjing Medical Center for Clinical Pharmacy, Nanjing, China.

出版信息

Int J Infect Dis. 2022 Oct;123:136-142. doi: 10.1016/j.ijid.2022.08.014. Epub 2022 Aug 23.

DOI:10.1016/j.ijid.2022.08.014
PMID:36028209
Abstract

OBJECTIVES

This study aimed to determine the thresholds of serum concentration as a predictor of tigecycline (TGC)-induced hypofibrinogenemia (HF) in critically ill patients.

METHODS

A retrospective cohort study was conducted in intensive care unit patients treated with TGC. The clinical data and serum concentration were extracted from the patients' electronic medical records. Patients were divided into an HF group and a normal group according to fibrinogen value. The receiver operating characteristic curves and logistic regression were used to derive serum concentration thresholds and quantify the association between exposure thresholds and HF while adjusting for confounders.

RESULTS

In total, 100 patients were included. The receiver operating characteristic curves analysis showed that TGC concentration parameters were strongly predictive of HF. Adjusting for duration of TGC, serum concentration at the 6 hours after the dosing (C) ≥ 0.645 mg/l, area under the concentration-time curve over a 24-hour period (AUC ) ≥ 20.76 mg·h/l, and serum concentration of 30 minutes before next dose (C) ≥ 0.455 mg/l were associated with a three- to five-fold increased risk of TGC-induced HF in logistic regression.

CONCLUSION

The findings from this study provide evidence that TGC exposure is highly predictive of HF, with an approximately three- to five-fold increased risk. Serum concentration at the 6 hours after the dosing (C) ≥ 0.645 mg/l with best area under the receiver operating characteristic curve and negative predictive value appears to be the most appropriate toxicity threshold.

摘要

目的

本研究旨在确定血清浓度阈值作为预测重症患者替加环素(TGC)诱导的低纤维蛋白原血症(HF)的指标。

方法

对接受 TGC 治疗的重症监护病房患者进行回顾性队列研究。从患者的电子病历中提取临床数据和血清浓度。根据纤维蛋白原值将患者分为 HF 组和正常组。使用受试者工作特征曲线和逻辑回归得出血清浓度阈值,并在调整混杂因素的情况下量化暴露阈值与 HF 之间的关联。

结果

共纳入 100 例患者。受试者工作特征曲线分析表明,TGC 浓度参数与 HF 具有很强的预测性。调整 TGC 持续时间后,6 小时后血清浓度(C)≥0.645mg/l、24 小时内浓度-时间曲线下面积(AUC)≥20.76mg·h/l、下一次给药前 30 分钟血清浓度(C)≥0.455mg/l 与 TGC 诱导 HF 的风险增加 3 至 5 倍相关。

结论

本研究结果表明,TGC 暴露与 HF 高度相关,风险增加约 3 至 5 倍。6 小时后血清浓度(C)≥0.645mg/l 时具有最佳的受试者工作特征曲线下面积和阴性预测值,似乎是最适合的毒性阈值。

相似文献

1
Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: A retrospective cohort study.血清浓度可预测危重症患者中替加环素引起的低纤维蛋白原血症:一项回顾性队列研究。
Int J Infect Dis. 2022 Oct;123:136-142. doi: 10.1016/j.ijid.2022.08.014. Epub 2022 Aug 23.
2
Machine learning-based prediction model for hypofibrinogenemia after tigecycline therapy.基于机器学习的替加环素治疗后低纤维蛋白原血症预测模型。
BMC Med Inform Decis Mak. 2024 Oct 4;24(1):284. doi: 10.1186/s12911-024-02694-x.
3
Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.评估浓度-时间曲线下面积与最低抑菌浓度(预估 AUIC)的比值,作为重症监护病房中多重耐药菌引起肺炎患者接受替加环素治疗结局的预测指标。
Int J Infect Dis. 2019 May;82:79-85. doi: 10.1016/j.ijid.2019.03.011. Epub 2019 Mar 13.
4
Tigecycline-associated hypofibrinogenemia in a real-world setting.替加环素相关的低纤维蛋白原血症的真实世界研究。
Int J Clin Pharm. 2020 Aug;42(4):1184-1189. doi: 10.1007/s11096-020-01072-7. Epub 2020 Jun 5.
5
Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature.大剂量替加环素引起的低纤维蛋白原血症——病例报告及文献复习
Medicine (Baltimore). 2020 Oct 23;99(43):e22638. doi: 10.1097/MD.0000000000022638.
6
Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study.替加环素在抗血栓治疗患者中的安全性:一项单中心回顾性研究。
Pharmacology. 2023;108(6):540-549. doi: 10.1159/000532001. Epub 2023 Sep 26.
7
Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.危重症患者替加环素相关性低纤维蛋白原血症的临床特征和危险因素。
Eur J Clin Pharmacol. 2020 Jul;76(7):913-922. doi: 10.1007/s00228-020-02860-w. Epub 2020 Apr 30.
8
Analysis of the clinical characteristics of tigecycline-induced hypofibrinogenemia.分析替加环素引起的低纤维蛋白原血症的临床特征。
J Chemother. 2023 Jul;35(4):292-297. doi: 10.1080/1120009X.2022.2105488. Epub 2022 Jul 29.
9
Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study.替加环素相关的低纤维蛋白原血症:一项单中心、回顾性、对照研究。
Thromb Res. 2024 Apr;236:155-160. doi: 10.1016/j.thromres.2024.03.003. Epub 2024 Mar 5.
10
High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.高剂量替加环素用于治疗多重耐药菌引起严重感染的重症患者。
Crit Care. 2014 May 5;18(3):R90. doi: 10.1186/cc13858.

引用本文的文献

1
Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System.使用美国食品药品监督管理局不良事件报告系统对药物性低纤维蛋白原血症进行药物警戒分析。
Int J Clin Pharm. 2025 Jan 31. doi: 10.1007/s11096-025-01867-6.
2
Mid-dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients.中剂量间隔浓度对重症患者的多黏菌素 B 暴露和急性肾损伤很重要。
CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1911-1921. doi: 10.1002/psp4.13040. Epub 2023 Sep 17.
3
Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
替加环素联合头孢哌酮/舒巴坦治疗与其他基于替加环素的联合治疗之间出血风险及低纤维蛋白原血症相关危险因素的比较。
Front Pharmacol. 2023 Jun 7;14:1182644. doi: 10.3389/fphar.2023.1182644. eCollection 2023.